Stocks and Investing
Stocks and Investing
Wed, July 29, 2015
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, July 28, 2015
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, July 27, 2015
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Aaron Gal Upgraded (BIIB) to Buy and Decreased Target to $385 on, Jul 27th, 2015
Aaron Gal of Bernstein, Upgraded "Biogen Inc." (BIIB) to Buy and Decreased Target from $436 to $385 on, Jul 27th, 2015.
Aaron has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Aaron's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $410 on, Wednesday, July 22nd, 2015
- Jay Olson of "Oppenheimer" Initiated at Hold on, Monday, April 27th, 2015
- Christopher Marai of "Nomura" Maintained at Hold with Increased Target to $442 on, Monday, April 27th, 2015
This is the rating of the analyst that currently disagrees with Aaron
- Geoffrey Porges of "Leerink Swann" Maintained at Buy with Decreased Target to $512 on, Thursday, June 11th, 2015
Contributing Sources